RP-HPLC Method Development and its Validation for Quantitative Determination of Rimonabant in Human Plasma
More details
Hide details
School of Pharmaceutical Sciences, Rajiv Gandhi Technological University, Gandhi Nagar, Bhopal, MP 462 036, India
Sagar Institute of Research and Technology, Bhopal, 462 036, MP, India
LBS College of Pharmacy, Jaipur, Rajasthan, 302 004, India
Deepti Jain   

School of Pharmaceutical Sciences, Rajiv Gandhi Technological University, Gandhi Nagar, Bhopal, MP 462 036, India
Publication date: 2017-11-02
Eurasian J Anal Chem 2012;7(3):115–122
A simple, accurate and precise HPLC method was developed and validated for determination of rimonabant in human plasma. Following liquid-liquid extraction, chromatographic separation was accomplished using C18 column with mobile phase consisting of acetonitrile: water (90:10, v/v), drug was detected at 260 nm. The LOD and LOQ were 3.3 and 9.9 ng mL-1, respectively. The method is linear in range 50-1000 ng mL-1. The average extraction recovery of drug from plasma was found 78.45%. The precision of method was found less than 2.8%, and accuracy was found between 97.12-101.71%. The assay may be applied to a pharmacokinetic and bioequivalence study of rimonabant.
Carai MAM, Colombo G and Gessa G L (2005) Rimonabant: The first therapeutically relevant cannabinoid antagonist. Life Sci 77: 2339.
Patel PN and Pathak RA (2007) Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. J Health-Syst Pharm 64(5): 481.
Rinaldi MC, Barth F, Heauime M, Shire D, Calandra B, Congy C, Aartinez S, Maruani J, Neliat G, Caput D, Ferra P, Soubrie P, Breliere JC and Le G (1994), SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350(2-3): 240.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J and Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295: 761.
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129.
McAllister SD, Griffin G, Satin LS and Abood ME (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 291(2), 618.
Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48(3): 443.
Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi C M, Le Fur G and Casellas P (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312(2): 637.
Rafael M and Fernando RF (2002) Cannabinoid Addiction: Behavioral Models and Neural Correlates. J Neurosci 21(9): 3326.
Vries TD, Shaham Y, Homberg J, Crombag H, Schuurman K, Dieben J, Vanderschuren L and Schoffelmeer A (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7(10): 1151.
Nirogi R, Kandikere V, Mudigonda K and Ajjala D (2008) Liquid chromatography tandem mass spectrometry method for the quantification of rimonabant, a CB1 receptor antagonist, in human plasma. Biomed Chromatogr 22(5): 469.
Satyanarayana RT, Kumar RM, Kumar KV, Raghavachary KSV, Varma MS, Rao CSNM and Swamy P Y (2009) A stability-indicating LC method for rimonabant. 69(1-2): 97.
Hsieh Y, Duncan CJG and Brisson JM (2007) Fused-core silica column highperformance liquid chromatography/tandem mass spectrometric determination of rimonabant in mouse plasma. Anal Chem 79: 5668.
Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), 2001.